The class A β-lactamase FTU-1 is native to Francisella tularensis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 666-671

  Antunes, Nuno T ^a   Frase, Hilary ^a   Toth, Marta ^a   Vakulenko, Sergei B ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZTREONAM; BETA LACTAMASE; CARBAPENEM; CARBAPENEMASE; CEFALOTIN; CEFEPIME; CEFMETAZOLE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CLAVULANIC ACID; CYSTEINE; DORIPENEM; ENZYME FTU 1; ERTAPENEM; IMIPENEM; LATAMOXEF; MEROPENEM; OXACILLIN; PENICILLIN G; PIPERACILLIN; SULBACTAM; TAZOBACTAM; TICARCILLIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CATALYSIS; DRUG HYDROLYSIS; FRANCISELLA TULARENSIS; FTU 1 GENE; GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PENICILLIN RESISTANCE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; ESCHERICHIA COLI; FRANCISELLA TULARENSIS; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA;

EID: 84856068251     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05305-11     Document Type: Article

References (43)

1. Barabote RD, et al. 2009. Complete genome sequence of Francisella tularensis subspecies holarctica FTNF002-00. PLoS One 4:e7041.
2. Beckstrom-Sternberg SM, et al. 2007. Complete genomic characterization of a pathogenic A.II strain of Francisella tularensis subspecies tularensis. PLoS One 2:e947.
3. Bina XR, Wang C, Miller MA, Bina JE. 2006. The Bla2 beta-lactamase from the live-vaccine strain of Francisella tularensis encodes a functional protein that is only active against penicillin-class beta-lactam antibiotics. Arch. Microbiol. 186:219-228. (Pubitemid 44273097)
4. Bush K, Jacoby GA. 2010. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54:969-976.
5. Chaibi EB, Sirot D, Paul G, Labia R. 1999. Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother. 43:447-458. (Pubitemid 29182292)
6. Champion MD, et al. 2009. Comparative genomic characterization of Francisella tularensis strains belonging to low and high virulence subspecies. PLoS Pathog. 5:e1000459.
7. Chaudhuri RR, et al. 2007. Genome sequencing shows that European isolates of Francisella tularensis subspecies tularensis are almost identical to US laboratory strain Schu S4. PLoS One 2:e352.
8. Clinical Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Copeland RA. 2000. Enzymes: a practical introduction to structure, mechanism, and data analysis, 2nd ed. Wiley-VCH, New York, NY.
10. Dixon M. 1953. The determination of enzyme inhibitor constants. Biochem. J. 55:170-171.
11. Eigelsbach HT, Braun W, Herring RD. 1951. Studies on the variation of Bacterium tularense. J. Bacteriol. 61:557-569.
12. Emanuelsson O, Brunak S, von Heijne G, Nielsen H. 2007. Locating proteins in the cell using Target P, Signal P and related tools. Nat. Protoc. 2:953-971. (Pubitemid 46745592)
13. Feldman KA, et al. 2001. An outbreak of primary pneumonic tularemia on Martha's Vineyard. N. Engl. J. Med. 345:1601-1606. (Pubitemid 33126839)
14. Fisher JF, Meroueh SO, Mobashery S. 2005. Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105:395-424. (Pubitemid 40351628)
15. Fournier PE, et al. 1998. Isolation of Francisella tularensis by centrifugation of shell vial cell culture from an inoculation eschar. J. Clin. Microbiol. 36:2782-2783.
16. Frase H, Shi Q, Testero SA, Mobashery S, Vakulenko SB. 2009. Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of beta-lactamases. J. Biol. Chem. 284:29509-29513.
17. Frase H, et al. 2011. Identification of products of inhibition of GES-2 beta-lactamase by tazobactam by X-ray crystallography and spectrometry. J. Biol. Chem. 286:14396-14409.
18. Frase H, Toth M, Champion MM, Antunes NT, Vakulenko SB. 2011. Importance of position 170 in the inhibition of GES-type β-lactamases by clavulanic acid. Antimicrob. Agents Chemother. 55:1556-1562.
19. Fujita O, Tatsumi M, Tanabayashi K, Yamada A. 2006. Development of a real-time PCR assay for detection and quantification of Francisella tularensis. Jpn. J. Infect. Dis. 59:46-51.
20. Gasteiger E, et al. 2003. ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 31:3784-3788. (Pubitemid 37442246)
21. Girlich D, Poirel L, Nordmann P. 2010. Novel ambler class A carbapenem-hydrolyzing β-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. Antimicrob. Agents Chemother. 54:328-332.
22. Gniadkowski M. 2008. Evolution of extended-spectrum beta-lactamases by mutation. Clin. Microbiol. Infect. 14(Suppl 1):11-32.
23. Gurycova D. 1998. First isolation of Francisella tularensis subsp. tularensis in Europe. Eur. J. Epidemiol. 14:797-802. (Pubitemid 29038341)
24. Haristoy X, et al. 2003. Francisella tularensis bacteremia. J. Clin. Microbiol. 41:2774-2776. (Pubitemid 36712515)
25. Hawkey PM. 2008. The growing burden of antimicrobial resistance. J. Antimicrob. Chemother. 62(Suppl. 1):i1-i9.
26. Henriques I, Moura A, Alves A, Saavedra MJ, Correia A. 2004. Molecular characterization of a carbapenem-hydrolyzing class A β-lactamase, SFC-1, from Serratia fonticola UTAD54. Antimicrob. Agents Chemother. 48:2321-2324. (Pubitemid 38691642)
27. Knox JR. 1995. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother. 39:2593-2601.
28. Larson CL, Wicht W, Jellison WL. 1955. A new organism resembling P. tularensis isolated from water. Public Health Rep. 70:253-258.
29. Larsson P, et al. 2009. Molecular evolutionary consequences of niche restriction in Francisella tularensis, a facultative intracellular pathogen. PLoS Pathog. 5:e1000472.
30. Larsson P, et al. 2005. The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat. Genet. 37:153-159.
31. Livermore DM, Woodford N. 2006. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14:413-420. (Pubitemid 44233298)
32. Olsufjev NG, Meshcheryakova IS. 1983. Subspecific Taxonomy of Francisella tularensis McCoy and Chapin 1912. Int. J. Syst. Bacteriol. 33:872-874. (Pubitemid 14243506)
33. Papp-Wallace KM, et al. 2010. Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A β-lactamase. Antimicrob. Agents Chemother. 54:890-897.
34. Petrosino JF, et al. 2006. Chromosome rearrangement and diversification of Francisella tularensis revealed by the type B (OSU18) genome sequence. J. Bacteriol. 188:6977-6985. (Pubitemid 44497910)
35. Pfeifer Y, Cullik A, Witte W. 2010. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int. J. Med. Microbiol. 300:371-379.
36. Poirel L, Brinas L, Verlinde A, Ide L, Nordmann P. 2005. BEL-1, a novel clavulanic acid-inhibited extended-spectrum β-lactamase, and the class 1 integron In120 in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:3743-3748. (Pubitemid 41233026)
37. Poirel L, et al. 2010. BEL-2, an extended-spectrum β-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:533-535.
38. Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P. 2000. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 44:622-632. (Pubitemid 30117952)
39. Rohmer L, et al. 2007. Comparison of Francisella tularensis genomes reveals evolutionary events associated with the emergence of human pathogenic strains. Genome Biol. 8:R102. doi:10.1186/gb-2007-8-6-r102.
40. Svensson K, et al. 2009. Landscape epidemiology of tularemia outbreaks in Sweden. Emerg. Infect. Dis. 15:1937-1947.
41. Walsh TR. 2010. Emerging carbapenemases: a global perspective. Int. J. Antimicrob. Agents 36(Suppl 3):S8-S14.
42. Walther-Rasmussen J, Hoiby N. 2007. Class A carbapenemases. J. Antimicrob. Chemother. 60:470-482. (Pubitemid 47299859)
43. Yigit H, et al. 2003. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2. Antimicrob. Agents Chemother. 47:3881-3889. (Pubitemid 37485004)